HSBC upgraded GSK to Hold from Reduce with a price target of 1,860 GBp, up from 1,500 GBp. The key risk for the stock was a large patent cliff and lack of pipeline strength to replace the earnings power, but the change in management and recent willingness to reinvest in the pipeline to drive future growth suggests that the company \"might be turning a corner,\" the analyst tells investors.
